Objective: Interleukin-1 (IL-1) is involved in the disease process of peritonitis. We hypothesize that IL-1 gene polymorphism may have an impact on the occurrence of peritonitis in uremic patients undergoing peritoneal dialysis (PD). Methods: Uremic patients were recruited for the study of IL-1β (–511) C/T gene polymorphism in 2002. These patients were then prospectively followed up to monitor their peritoneal membrane characteristics, biochemical parameters, occurrence of peritonitis and patient as well as PD technique survival. Results: A total of 74 patients were enrolled in the study. During follow-up, at least one episode of peritonitis occurred in 36 patients. Compared with patients without peritonitis, the carriage of C allele in IL-1β gene polymorphism (C/C and C/T genotypes) was significantly associated with the occurrence of peritonitis (p = 0.013). This was further confirmed in the multivariate logistic regression analysis (odds ratio 8.18, p = 0.017). Conclusion: Carriers of C allele were associated with an increased risk of peritonitis.

Keywords:
Peritoneal dialysis, Peritonitis, Interleukin-1β, Gene polymorphism
1.
Afolalu B, Troidle L, Osayimwen O, Bhargava J, Kitsen J, Finkelstein FO: Technique failure and center size in a large cohort of peritoneal dialysis patients in a defined geographic area. Perit Dial Int 2009;29:292–296.
2.
Maiorca R, Cancarini GC, Zubani R, Camerini C, Manili L, Brunori G, et al: CAPD viability: a long-term comparison with hemodialysis. Perit Dial Int 1996;16:276–287.
3.
Genestier S, Hedelin G, Schaffer P, Faller B: Prognostic factors in CAPD patients: a retrospective study of a 10-year period. Nephrol Dial Transplant 1995;10:1905–1911.
4.
Piraino B, Bailie GR, Bernardini J, et al: ISPD guidelines/recommendations. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int 2005;25:107–131.
5.
Dinarello CA: Interleukin-1, interleukin-1 receptors, and interleukin-1 receptor antagonist. Int Rev Immunol 1998;16:457–499.
6.
Stuber F: Effect of genomic polymorphisms on the course of sepsis: is there a concept for gene therapy? J Am Soc Nephrol 2001;12(suppl 17):S60–S64.
7.
Chan HL, Tse AM, Zhang MD, Wong VW, Chim AM, Hui AY, et al: Genetic polymorphisms of interleukin-1β in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese. Aliment Pharmacol Ther 2006;23:1703–1711.
8.
Zhang PA, Li Y, Xu P, Wu JM: Polymorphisms of interleukin-1β and interleukin-1 receptor antagonist genes in patients with chronic hepatitis B. World J Gastroenterol 2004;10:1826–1829.
9.
Rodrigo E, Sánchez-Velasco P, Ruiz JC, Fernández-Fresnedo G, López-Hoyos M, Piñera C, et al: Cytokine polymorphisms and risk of infection after kidney transplantation. Transplant Proc 2007;39:2219–2221.
10.
Hirankarn N, Kimkong I, Kummee P, Tangkijvanich P, Poovorawan Y: Interleukin-1β gene polymorphism associated with hepatocellular carcinoma in hepatitis B virus infection. World J Gastroenterol 2006;12:776–779.
11.
Di Giovine FS, Takhsh E, Blakemore AIF, Duff GW: Single base polymorphism at –511 in the human interleukin-1β gene. Hum Mol Genet 1992;1:450.
12.
Dinarello CA: Interleukin-1, interleukin-1 receptors, and interleukin-1 receptor antagonist. Int Rev Immunol 1998;16:457–499.
13.
Rodríguez-Ramos C, Galan F, Díaz F, Elvira J, Martín-Herrera L, Girón-González JA: Expression of proinflammatory cytokines and their inhibitors during the course of spontaneous bacterial peritonitis. Dig Dis Sci 2001;46:1668–1676.
14.
Enríquez J, Klínger J, Arturo JA, Delgado M, Tobar C, Mosquera M: Peritonitis in continuous ambulatory peritoneal dialysis: cytokines in peritoneal fluid and blood. Adv Perit Dial 2002;18:177–183.
15.
Fleren MW: Mechanisms regulating cytokine release from peritoneal macrophages during continuous ambulatory peritoneal dialysis. Blood Purif 1996;14:179–187.
16.
Yao V, McCauley R, Cooper D, Platell C, Hall JC: Peritoneal mesothelial cells produce cytokines in a murine model of peritonitis. Surg Infect (Larchmt) 2004;5:229–236.
17.
Witowski J, Tayama H, Ksiazek K, Wanic-Kossowska M, Bender TO, Jörres A: Human peritoneal fibroblasts are a potent source of neutrophil-targeting cytokines: a key role of IL-1β stimulation. Lab Invest 2009;89:414–424.
18.
Hall SK, Perregaux DG, Gabel CA, Woodworth T, Durham LK, Huizinga TW, et al: Correlation of polymorphic variation in the promoter region of the interleukin-1β gene with secretion of interleukin-1β protein. Arthritis Rheum 2004;50:1976–1983.
19.
Santtila S, Savinainen K, Hurme M: Presence of the IL-1RA allele 2 (IL-1RN*2) is associated with enhanced IL-1 production in vitro. Scand J Immunol 1998;47:195–198.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.